Objectives: To assess the effect of Permethrin 5% cream versus metronidazole 0.75% gel on skin region in patients with papulopustular rosacea.
Design: a randomized clinical trial.
Setting and conduct: The eligible patients with papulopustular rosacea who will refer to Farshchian Hospital during the study period will be enrolled into the trial.
Inclusion criteria: affected with papulopustular rosacea.
Exclusion criteria: mild rosacea stage 1 with mild erythema without lesions; presence of ocular signs or symptoms; steroidal rosacea; previous history of sensitivity to permethrin or metronidazole; breastfeeding.
Intervention group: Treatment with topical permethrin 5% cream twice a day for 12 weeks.
Control group: Treatment with topical metronidazole 0.75% gel twice a day for 12 weeks.
Primary outcome: Assessing the number of papule and pustule before treatment and 6 and 12 weeks after treatment by physical examination.
Secondary outcome: Scoring the erythema of skin lesions using Investigator Global Assesment (IGA) before treatment and 6 and 12 weeks after treatment.
General information
Acronym
IRCT registration information
IRCT registration number:IRCT201508169014N75
Registration date:2015-08-25, 1394/06/03
Registration timing:registered_while_recruiting
Last update:
Update count:0
Registration date
2015-08-25, 1394/06/03
Registrant information
Name
Jalal Poorolajal
Name of organization / entity
Department of Epidemiology & Biostatistics Hamadan University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 81 1838 0090
Email address
poorolajal@umsha.ac.ir
Recruitment status
Recruitment complete
Funding source
Vice-chancellor for Research the Technology, Hamadan University of Medical Sciences
Expected recruitment start date
2013-12-22, 1392/10/01
Expected recruitment end date
2016-01-20, 1394/10/30
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Effect of permethrin 5% cream versus metronidazole 0.75% gel on skin region in patients with papulopustular rosacea: a randomized clinical trial
Public title
Effect of permethrin 5% cream versus metronidazole 0.75% gel on skin region in patients with papulopustular rosacea
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria: affected with papulopustular rosacea.
Exclusion criteria: mild rosacea stage 1 with mild erythema without lesions; presence of ocular signs or symptoms; steroidal rosacea; previous history of sensitivity to permethrin or metronidazole; breastfeeding.
Age
No age limit
Gender
Both
Phase
2
Groups that have been masked
No information
Sample size
Target sample size:
40
Randomization (investigator's opinion)
Randomized
Randomization description
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethic Committee of Hamadan University of Medical Sciences
Street address
Vice-chancellor for Research the Technology, Hamadan University of Medical Sciences, Shahid Fahmideh Ave
City
Hamadan
Postal code
6517838695
Approval date
2014-01-13, 1392/10/23
Ethics committee reference number
D/P/16/35/9/3562
Health conditions studied
1
Description of health condition studied
Papulopustular rosacea
ICD-10 code
L71
ICD-10 code description
Rosacea
Primary outcomes
1
Description
Assessing the number of papule and pustule
Timepoint
before treatment and 6 and 12 weeks after treatment
Method of measurement
by physical examination
Secondary outcomes
1
Description
Scoring the erythema of skin lesions
Timepoint
before treatment and 6 and 12 weeks after treatment
Method of measurement
using Investigator Global Assesment (IGA)
Intervention groups
1
Description
Treatment with topical permethrin 5% cream twice a day for 12 weeks
Category
Treatment - Drugs
2
Description
Treatment with topical metronidazole 0.75% gel twice a day for 12 weeks
Category
Treatment - Drugs
Recruitment centers
1
Recruitment center
Name of recruitment center
Farshchian Hospital
Full name of responsible person
Dr Zoha Dehnavi
Street address
Farshchian Hospital, Mirzadeh Eshghi Ave.
City
Hamadan
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Vice-chancellor for Research the Technology, Hamadan University of Medical Sciences
Full name of responsible person
Dr Saeid Bashirian
Street address
Hamadan University of Medical Sciences, Shahid Fahmideh Ave
City
Hamadan
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Vice-chancellor for Research the Technology, Hamadan University of Medical Sciences
Proportion provided by this source
100
Public or private sector
empty
Domestic or foreign origin
empty
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
empty
Person responsible for general inquiries
Contact
Name of organization / entity
Farshchian Hospital
Full name of responsible person
Dr Zoha Dehnavi
Position
Resident of Dermatology
Other areas of specialty/work
Street address
Farshchian Hospital, Mirzadeh Eshghi Ave.
City
Hamadan
Postal code
Phone
+98 81 3827 4184
Fax
Email
zoha_de_f@yahoo.com
Web page address
Person responsible for scientific inquiries
Contact
Name of organization / entity
Farshchian Hospital
Full name of responsible person
Dr Gholamreza Eshghi
Position
Dermatologist
Other areas of specialty/work
Street address
Farshchian Hospital, Mirzadeh Eshghi Ave.
City
Hamadan
Postal code
Phone
+98 81 3827 4184
Fax
Email
gholamrezaeshghi58@gmail.com
Web page address
Person responsible for updating data
Contact
Name of organization / entity
Department of Epidemiology
Full name of responsible person
Dr Jalal Poorolajal
Position
Associate Professor
Other areas of specialty/work
Street address
School of Public Health, Hamadan University of Medical Sciences, Shahid Fahmideh Ave
City
Hamadan
Postal code
6517838695
Phone
+98 81 3838 0090
Fax
Email
poorolajal@umsha.ac.ir
Web page address
Sharing plan
Deidentified Individual Participant Data Set (IPD)